No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.
This analysis addresses risk of breast cancer among women in BRCA-positive families who test negative for the family mutation. We compared the number of prospectively diagnosed breast cancers in 395 mutation-negative women from 28 BRCA1/2-positive families to an age-, race-, and calendar time-specific expected number of breast cancers derived from the SEER 9 Cancer Registry. Study participants contributed a total of 7008.1 person-years of follow-up. The mean age at study entry was 31.3 years; mean follow-up was 17.7 years. Ten women developed breast cancer yielding an observed-to-expected ratio of 0.82 (95% CI 0.39-1.51). Adjustment for possible reduction in breast cancer risk due to oophorectomy by two different methods resulted in O/E ratios in the range of 0.80-0.99. Stratification by degree of relatedness to the nearest mutation carrier did not substantially alter these results, however, women with at least one-first degree relative with breast cancer appeared to have a slightly increased, though not statistically significant, risk of breast cancer (O/E ratio = 1.33, 95% CI 0.41-2.91). Our data suggest that breast cancer risk among mutation-negative women from BRCA1/2 mutation-positive families is similar to that observed in the general population, with a possible slight increase in risk among mutation-negative women with a family history of breast cancer in a first degree relative. Although this is the largest prospective cohort yet assembled to address this important question, the number of breast cancer events is still relatively small.
Korde
Larissa A
LA
Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 825 Eastlake Ave, E., G3-630, Seattle, WA 98109, USA. Lkorde@u.washington.edu
Mueller
Christine M
CM
Loud
Jennifer T
JT
Struewing
Jeffery P
JP
Nichols
Kathy
K
Greene
Mark H
MH
Mai
Phuong L
PL
D000328:Adult; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000517:prevention & control; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D016017:Odds Ratio; D010052:Ovariectomy; D010375:Pedigree; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D018426:SEER Program; D013997:Time Factors; D014481:United States
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human
J Med Genet. 2007 Aug;44(8):e89; author reply e88
17673443
Breast Cancer Res Treat. 2010 Jan;119(2):409-14
19885732
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Genet Test. 2004 Fall;8(3):222-8
15727243
J Clin Oncol. 2005 Oct 20;23(30):7491-6
16234515
J Med Genet. 2007 Apr;44(4):e76
17400795
Eur J Surg Oncol. 2006 Dec;32(10):1231-4
16626923
Lancet Oncol. 2007 Dec;8(12):1042-1043
18054868
J Med Genet. 2007 Jan;44(1):10-15
17079251
Am J Hum Genet. 2003 May;72(5):1117-30
12677558